Issue 34

AWAKN LIFE SCIENCES LISTS ON THE NEO EXCHANGE

Today, Canadian-based biotechnology company Awakn Life Sciences began trading on the NEO Exchange under the symbol AWKN.

The company’s focus is the treatment of addiction with psychedelic drugs, therapies and technologies, in the pursuit of providing hope for people for whom the current treatment methodologies are not working, CEO Anthony Tennyson told PSYCH following the company’s debut on the exchange.

‘That requires big money, and that’s what the capital market strategy is all about. Yes, it’s about creating shareholder value, but it’s actually about having access to capital to run our projects to achieve our passion,’ Tennyson said.

Read More

RISING TIDES: NORTH AMERICAN DRUG REGULATIONS AND THE IMPACT ON BIG PSYCHEDELIC BUSINESS – PART 2

With narrow channels for psychedelic access in North America’s current regulatory frameworks, what opportunities do current regulations create and how are companies currently creating revenue streams in these restrictive environments?

This two-part series examines the commercial implications of regulatory frameworks and proposed changes in North America.

Read More

BUSINESS AND INVESTMENT

Awakn Life Sciences publishes evidence of MDMA’s therapeutic potential.

German psychedelics start-up atai valued at US$3.19 billion following strong Nasdaq debut.

Numinus Wellness advancements evident after TSX Venture Exchange up-listing.

Cybin completes 51st study of psychedelic compounds for therapeutic applications.

atai founder says IPO funds will fuel development of psychedelic medical products.

Core One Labs to patent biosynthesised psilocybin for medical psychedelic market.

Revive Therapeutics partners with Antigua university to pioneer clinical research of psychedelics.

Red Light Holland to acquire 51% stake in gourmet mushroom production facility.

Psychedelic IPOs build momentum as Atai Life Sciences goes public.

Ketamine One highlights psychedelic research and announces new clinical trial.

MINDCURE develops two proprietary ketamine-enhanced protocols for psychedelic-assisted psychotherapy.

Algernon Pharmaceuticals targets first human study for its DMT stroke programme.

Silo Wellness and Entheon Biomedical partner to promote Psychedelics Genetic Test Kit.

Small Pharma starts clinical trial of DMT-based treatment for severe depression.

Psyence to collaborate with Jamaica’s Scientific Research Council to develop psilocybin product.

Advances in psychedelics could change investors’ minds.

Mydecine identifies four psychedelic drug candidates to combat mental health issues.

Canadian government funds Braxia Scientific’s world-first ketamine trial for bipolar depression.

Core One Labs plans share consolidation ahead of common shares Nasdaq listing.

Black founders in cannabis and psychedelics changing how we think about drugs.

New service to provide 100 million Americans with greater access to psychedelic psychotherapy.

Dimensions Health Centres to fund psychedelics research at Queen’s University.

Algernon Pharmaceuticals’ CEO discusses major breakthrough towards treating strokes with psychedelic compound.

Diamond Therapeutics selects BioPharma Services for first-phase clinical trial. 

Core One Labs retains Canada’s highest-ranked IP law firm.

Akome commences development of psychedelic drug formula for mitigating stroke damage.

Clearmind Medicine announces increase to previously announced non-brokered private placement.

Eastra Health appoints veteran pharmacologist and neuroscientist as Chief Scientific Officer.

PSYCH Investor Summit: Research and Development

How can successful for-profit psychedelics organisations and investors support the change-making work of non-profits? What is the role of each in an increasingly competitive business ecosystem, where are the friction points and what does the ideal relationship look like?

Join us on 7 July for a highly anticipated discussion between atai Life Sciences’ founder, Christian Angermayer and Multidisciplinary Association for Psychedelic Studies (MAPS) founder, Rick Doblin at the PSYCH Investor Summit: Research and Development

In a US$100 billion industry set to disrupt modern healthcare, hear these important insights and more on the critical path forward from leaders on the frontlines. Secure your tickets and visit the event page for more information.

Register Now

RESEARCH AND SCIENCE

Ketamine might help alcohol addiction by rewiring the brain.

Could MDMA help people suffering from trauma and addiction?

University of Alabama studying benefits of psilocybin for treating addiction and pain.

Can ketamine be an effective cure for PTSD?

How doctors and patients alike came around to ketamine.

British Columbia health researchers experimenting with psychedelic drugs for mental health disorders.

Canadian healthcare workers taking psilocybin to better understand psychedelic therapy process.

PSYCH Investor Summit: Research & Development

In today’s fast-moving psychedelics industry, brand awareness and thought leadership in front of a qualified audience are crucial for growing operators. Would your organisation benefit from connecting with a network of investors ready to deploy capital? Partnership opportunities for the upcoming PSYCH Investor Summit: Research & Development are still available. Enquire with our team to learn more.

Apply to Partner

REGULATION AND LEGISLATION

Louisiana governor signs cannabis decriminalisation bill into law.

Can psychedelics help make dying easier?

California senator says psychedelics bill is a step towards decriminalising all drugs.

Australian psychedelics advocacy group calls for legislation change to allow psychedelics access.

Oregon’s psilocybin programme starts to take shape.

Partner with us